skip to main content
Idioma:
previous page 1 Resultados 2 3 4 5 next page
Mostrar solo
Result Number Material Type Add to My Shelf Action Record Details and Options
11
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity
Material Type:
Artículo 		Añadir a Mi Portal

The clinical KRAS(G12C) inhibitor AMG 510 drives anti-tumour immunity

Canon, Jude ; Rex, Karen ; Saiki, Anne Y ; Mohr, Christopher ; Cooke, Keegan ; Bagal, Dhanashri ; Gaida, Kevin ; Holt, Tyler ; Knutson, Charles G ; Koppada, Neelima ; Lanman, Brian A ; Werner, Jonathan ; Rapaport, Aaron S ; San Miguel, Tisha ; Ortiz, Roberto ; Osgood, Tao ; Sun, Ji-Rong ; Zhu, Xiaochun ; McCarter, John D ; Volak, Laurie P ; Houk, Brett E ; Fakih, Marwan G ; O'Neil, Bert H ; Price, Timothy J ; Falchook, Gerald S ; Desai, Jayesh ; Kuo, James ; Govindan, Ramaswamy ; Hong, David S ; Ouyang, Wenjun ; Henary, Haby ; Arvedson, Tara ; Cee, Victor J ; Lipford, J Russell

Nature (London), 2019-11, Vol.575 (7781), p.217-223 [Revista revisada por pares]

England: Nature Publishing Group

Texto completo disponible

Citas Citado por
12
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study
Material Type:
Artículo 		Añadir a Mi Portal

Evaluation of BGJ398, a Fibroblast Growth Factor Receptor 1-3 Kinase Inhibitor, in Patients With Advanced Solid Tumors Harboring Genetic Alterations in Fibroblast Growth Factor Receptors: Results of a Global Phase I, Dose-Escalation and Dose-Expansion Study

Nogova, Lucia ; Sequist, Lecia V ; Perez Garcia, Jose Manuel ; Andre, Fabrice ; Delord, Jean-Pierre ; Hidalgo, Manuel ; Schellens, Jan H M ; Cassier, Philippe A ; Camidge, D Ross ; Schuler, Martin ; Vaishampayan, Ulka ; Burris, Howard ; Tian, G Gary ; Campone, Mario ; Wainberg, Zev A ; Lim, Wan-Teck ; LoRusso, Patricia ; Shapiro, Geoffrey I ; Parker, Katie ; Chen, Xueying ; Choudhury, Somesh ; Ringeisen, Francois ; Graus-Porta, Diana ; Porter, Dale ; Isaacs, Randi ; Buettner, Reinhard ; Wolf, Jürgen

Journal of clinical oncology, 2017-01, Vol.35 (2), p.157-165 [Revista revisada por pares]

United States: American Society of Clinical Oncology

Texto completo disponible

Citas Citado por
13
Functional Pyrazolo[1,5- a ]pyrimidines: Current Approaches in Synthetic Transformations and Uses As an Antitumor Scaffold
Functional Pyrazolo[1,5- a ]pyrimidines: Current Approaches in Synthetic Transformations and Uses As an Antitumor Scaffold
Material Type:
Artículo 		Añadir a Mi Portal

Functional Pyrazolo[1,5- a ]pyrimidines: Current Approaches in Synthetic Transformations and Uses As an Antitumor Scaffold

Arias-Gómez, Andres ; Godoy, Andrés ; Portilla, Jaime

Molecules (Basel, Switzerland), 2021-05, Vol.26 (9), p.2708 [Revista revisada por pares]

Switzerland: MDPI AG

Texto completo disponible

Citas Citado por
14
Biological Evaluation and Molecular Docking with In Silico Physicochemical, Pharmacokinetic and Toxicity Prediction of Pyrazolo[1,5- a ]pyrimidines
Biological Evaluation and Molecular Docking with In Silico Physicochemical, Pharmacokinetic and Toxicity Prediction of Pyrazolo[1,5- a ]pyrimidines
Material Type:
Artículo 		Añadir a Mi Portal

Biological Evaluation and Molecular Docking with In Silico Physicochemical, Pharmacokinetic and Toxicity Prediction of Pyrazolo[1,5- a ]pyrimidines

Naglah, Ahmed M ; Askar, Ahmed A ; Hassan, Ashraf S ; Khatab, Tamer K ; Al-Omar, Mohamed A ; Bhat, Mashooq A

Molecules (Basel, Switzerland), 2020-03, Vol.25 (6), p.1431 [Revista revisada por pares]

Switzerland: MDPI AG

Texto completo disponible

Citas Citado por
15
Risdiplam in Type 1 Spinal Muscular Atrophy
Risdiplam in Type 1 Spinal Muscular Atrophy
Material Type:
Artículo 		Añadir a Mi Portal

Risdiplam in Type 1 Spinal Muscular Atrophy

Baranello, Giovanni ; Darras, Basil T ; Day, John W ; Deconinck, Nicolas ; Klein, Andrea ; Masson, Riccardo ; Mercuri, Eugenio ; Rose, Kristy ; El-Khairi, Muna ; Gerber, Marianne ; Gorni, Ksenija ; Khwaja, Omar ; Kletzl, Heidemarie ; Scalco, Renata S ; Seabrook, Timothy ; Fontoura, Paulo ; Servais, Laurent

The New England journal of medicine, 2021-03, Vol.384 (10), p.915-923 [Revista revisada por pares]

United States: Massachusetts Medical Society

Texto completo disponible

Citas Citado por
16
Synthesis of 2Ð-azolo[1,5-а][1,2,3]triazolo[4,5-е]pyrimidines
Synthesis of 2Ð-azolo[1,5-а][1,2,3]triazolo[4,5-е]pyrimidines
Material Type:
Artículo 		Añadir a Mi Portal

Synthesis of 2Ð-azolo[1,5-а][1,2,3]triazolo[4,5-е]pyrimidines

Gorbunov, Evgeny B ; Rusinov, Gennady L ; Ulomskii, Evgeny N ; Isenov, Maksim L ; Charushin, Valery N

Chemistry of heterocyclic compounds (New York, N.Y. 1965), 2015-05, Vol.51 (5), p.491 [Revista revisada por pares]

Springer

Texto completo disponible

Citas Citado por
17
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study
Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study
Material Type:
Artículo 		Añadir a Mi Portal

Futibatinib, an Irreversible FGFR1-4 Inhibitor, in Patients with Advanced Solid Tumors Harboring FGF / FGFR Aberrations: A Phase I Dose-Expansion Study

Meric-Bernstam, Funda ; Bahleda, Rastislav ; Hierro, Cinta ; Sanson, Marc ; Bridgewater, John ; Arkenau, Hendrik-Tobias ; Tran, Ben ; Kelley, Robin Kate ; Park, Joon Oh ; Javle, Milind ; He, Yaohua ; Benhadji, Karim A ; Goyal, Lipika

Cancer discovery, 2022-02, Vol.12 (2), p.402-415

United States: American Association for Cancer Research

Texto completo disponible

Citas Citado por
18
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia
Material Type:
Artículo 		Añadir a Mi Portal

Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

Byrd, John C ; Furman, Richard R ; Coutre, Steven E ; Flinn, Ian W ; Burger, Jan A ; Blum, Kristie A ; Grant, Barbara ; Sharman, Jeff P ; Coleman, Morton ; Wierda, William G ; Jones, Jeffrey A ; Zhao, Weiqiang ; Heerema, Nyla A ; Johnson, Amy J ; Sukbuntherng, Juthamas ; Chang, Betty Y ; Clow, Fong ; Hedrick, Eric ; Buggy, Joseph J ; James, Danelle F ; O'Brien, Susan

The New England journal of medicine, 2013-07, Vol.369 (1), p.32-42 [Revista revisada por pares]

Waltham, MA: Massachusetts Medical Society

Texto completo disponible

Citas Citado por
19
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial
Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial
Material Type:
Artículo 		Añadir a Mi Portal

Safety, tolerability, pharmacokinetics, and pharmacodynamics of GLPG1690, a novel autotaxin inhibitor, to treat idiopathic pulmonary fibrosis (FLORA): a phase 2a randomised placebo-controlled trial

Maher, Toby M ; van der Aar, Ellen M ; Van de Steen, Olivier ; Allamassey, Lisa ; Desrivot, Julie ; Dupont, Sonia ; Fagard, Liesbeth ; Ford, Paul ; Fieuw, Ann ; Wuyts, Wim

The lancet respiratory medicine, 2018-08, Vol.6 (8), p.627-635 [Revista revisada por pares]

England: Elsevier Ltd

Texto completo disponible

Citas Citado por
20
Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery
Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery
Material Type:
Artículo 		Añadir a Mi Portal

Pyrimidine-fused Dinitrogenous Penta-heterocycles as a Privileged Scaffold for Anti-Cancer Drug Discovery

Li, Wen ; Zhang, Jinyang ; Wang, Min ; Dong, Ru ; Zhou, Xin ; Zheng, Xin ; Sun, Liping

Current topics in medicinal chemistry, 2022-02, Vol.22 (4), p.284-304 [Revista revisada por pares]

Texto completo disponible

Citas Citado por
previous page 1 Resultados 2 3 4 5 next page

Personalizar los resultados

  1. Editar

Refine Search Results

Ampliar mis resultados

  1.   

Mostrar solo

  1. Recursos en línea (78.453)
  2. Revistas arbitradas (62.280)
  3. Disponible (3)

Fecha de Publicación 

De Hasta
Refinar
  1. Antes de1961  (1.032)
  2. 1961Hasta1975  (7.691)
  3. 1976Hasta1990  (12.330)
  4. 1991Hasta2006  (21.524)
  5. Después de 2006  (56.033)
  6. Más opciones open sub menu

Idioma 

  1. Inglés  (94.204)
  2. Japonés  (10.706)
  3. Alemán  (1.084)
  4. Francés  (761)
  5. Ruso  (717)
  6. Chino  (466)
  7. Italiano  (275)
  8. Español  (231)
  9. Portugués  (115)
  10. Polaco  (115)
  11. Húngaro  (55)
  12. Czech  (53)
  13. Holandés  (44)
  14. Noruego  (30)
  15. Ucraniano  (28)
  16. Danés  (25)
  17. Sueco  (22)
  18. Croatian  (20)
  19. Turco  (16)
  20. Rumano  (15)
  21. Más opciones open sub menu

Nuevas sugerencias de búsqueda

Ignorar mi consulta y buscar por todo

por este autor/creador:

  1. Chiari, L
  2. Hurst, D
  3. Symposium on Purine and Pyrimidine Metabolism
  4. Silva, A

con este tema:

  1. Science & Technology
  2. Life Sciences & Biomedicine
  3. Humans
  4. Pyrimidines
  5. Animals

  • Realización: ABCD-USP USP   Logos de Redes Sociales: Freepik

Buscando en bases de datos remotas, por favor espere

  • Buscando por
  • enscope:(USP_VIDEOS),scope:("PRIMO"),scope:(USP_FISICO),scope:(USP_EREVISTAS),scope:(USP),scope:(USP_EBOOKS),scope:(USP_PRODUCAO),primo_central_multiple_fe
  • Mostrar lo que tiene hasta ahora